<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371981</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02670</org_study_id>
    <secondary_id>NCI-2011-02670</secondary_id>
    <secondary_id>CDR0000701850</secondary_id>
    <secondary_id>AAML1031</secondary_id>
    <secondary_id>COG-AAML1031</secondary_id>
    <secondary_id>S12-02301</secondary_id>
    <secondary_id>AAML1031</secondary_id>
    <secondary_id>AAML1031</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT01371981</nct_id>
  </id_info>
  <brief_title>Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in
      treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib
      tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell
      growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells,
      either by killing the cells or by stopping them from dividing. Giving bortezomib and
      sorafenib tosylate together with combination chemotherapy may be an effective treatment for
      acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare event-free survival (EFS) and overall survival (OS) in patients with de novo
      acute myeloid leukemia (AML) without high allelic ratio fms-like tyrosine kinase
      (FLT3)/internal tandem duplications (ITD)+ mutations who are randomized to standard therapy
      versus bortezomib/standard combination therapy.

      II. To determine the feasibility of combining bortezomib with standard chemotherapy in
      patients with de novo AML.

      III. To compare the OS and EFS of high-risk patients treated with intensive Induction II with
      historical controls from AAML03P1 and AAML0531.

      IV. To determine the feasibility of administering sorafenib (sorafenib tosylate) with
      standard chemotherapy and in a one year maintenance phase in patients with de novo high
      allelic ratio FLT3/ITD+ AML.

      SECONDARY OBJECTIVES:

      I. To assess the anti-leukemic activity of sorafenib in patients with de novo high allelic
      ratio FLT3/ITD+ AML.

      II. To compare the percentage of patients converting from positive minimal residual disease
      (MRD) to negative MRD after Intensive Induction II with historical controls from AAML03P1 and
      AAML0531.

      III. To compare OS, disease-free survival (DFS), cumulative incidence of relapse, and
      treatment-related mortality from end of Intensification I between patients allocated to best
      allogenic donor stem cell transplant (SCT) and comparable patients on AAML0531 who did not
      receive allogenic donor SCT.

      IV. To compare OS, DFS, cumulative incidence of relapse, treatment-related mortality, and
      severe toxicity between patients allocated to matched family donor SCT on AAML1031 and
      AAML0531.

      V. To assess the health-related quality of life (HRQOL) of patients treated with chemotherapy
      and stem cell transplant (SCT) for AML.

      VI. To evaluate bortezomib pharmacokinetics (PK) in patients receiving the combination
      regimen.

      VII. To obtain sorafenib and metabolite steady state pharmacokinetics and
      pharmacokinetic-pharmacodynamic data in subjects with FLT3/ITD receiving sorafenib.

      VIII. To compare the changes in shortening fraction/ejection fraction over time between
      patients treated with and without dexrazoxane.

      IX. To refine the use of minimal-residual disease (MRD) detection with 4-color flow
      cytometry.

      X. To evaluate the prognostic significance of molecular MRD and its contribution to risk
      identification with multidimensional flow cytometry (MDF)-based MRD in patients with
      translocations amenable to quantitative real time (RT)-polymerase chain reaction (PCR) (e.g.,
      t[8;21], inv[16], t[9;11], Wilms tumor 1 [WT1] expression).

      XI. To determine the leukemic involvement of the hematopoietic early progenitor cell and its
      role in defining response to therapy.

      XII. To define the leukemic stem cell population in patients with AML. XIII. To determine the
      prevalence and prognostic significance of molecular abnormalities of WT1, runt-related
      transcription factor (RUNX)1, mixed-lineage leukemia (MLL)-partial tandem duplication (PTD),
      tet methylcytosine dioxygenase 2 (TET2), Cbl proto-oncogene, E3 ubiquitin protein ligase
      (c-CBL), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), and other novel
      AML-associated genes in pediatric AML.

      XIV. Correlate the expression of cluster of differentiation (CD)74 antigen as well as
      proteasome beta 5-subunit (PSMB5) gene expression and mutation with response to bortezomib.

      XV. To evaluate the changes in protein expression and unfolded protein response (UPR) in
      patients with AML.

      XVI. To determine the expression level of wild-type FLT3, and correlate with outcome and in
      vitro sensitivity to FLT3 inhibition.

      XVII. To collect biology specimens at diagnosis, treatment time points, and relapse for
      future biology studies XVIII. To create a pediatric-specific algorithm to predict the
      occurrence of grade 2-4 acute graft-versus-host disease (GVHD) prior to its clinical
      manifestations using a combination of pre-transplant clinical variables and serum GVHD
      biomarker concentrations in the first weeks after SCT.

      OUTLINE: This is a dose-escalation study of sorafenib tosylate. Patients are randomized to
      Arm A or B or offered treatment on 1 of 6 arms. (Arms A and B are closed to new patient
      enrollment as of 02/04/2016)

      Arm A:

      INDUCTION I: Patients receive cytarabine intrathecally (IT) on day 1 and ADE chemotherapy
      comprising cytarabine intravenously (IV) over 1-30 minutes on days 1-10; daunorubicin
      hydrochloride IV over 1-15 minutes on days 1, 3, and 5; and etoposide IV over 1-2 hours on
      days 1-5.

      INDUCTION II: Patients with low risk (LR) receive cytarabine IT and ADE chemotherapy as in
      Induction I. Patients with high risk (HR) receive cytarabine IT on day 1 and MA chemotherapy
      comprising high-dose cytarabine IV over 1-3 hours on days 1-4, and mitoxantrone IV over 15-30
      minutes on days 3-6. Patients who achieve complete remission (CR) proceed to Intensification
      I (beginning on day 37). Patients with refractory disease are off protocol therapy.

      INTENSIFICATION I: Patients receive cytarabine IT on day 1 and AE chemotherapy comprising
      high-dose cytarabine IV over 1-3 hours, and etoposide IV over 1-2 hours on days 1-5. Patients
      who achieve CR proceed to Intensification II or stem cell transplantation (SCT) beginning on
      day 34. Patients with refractory disease are off protocol therapy.

      INTENSIFICATION II: Patients with LR receive cytarabine IT on day 1 and MA chemotherapy as in
      Induction II. Patients with HR and no donor for SCT receive high-dose cytarabine IV over 3
      hours on days 1, 2, 8, and 9 and asparaginase intramuscularly (IM) on days 2 and 9.

      STEM CELL TRANSPLANTATION (SCT) (HR patients with matched family [MFD] or unrelated donor):

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes once daily on
      days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of
      busulfan.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO beginning on day -2 and
      continuing until day 98 (matched sibling donor) or day 180 (with taper) (other
      related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched
      sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients
      with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.

      Arm B:

      INDUCTION I: Patients receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A.
      Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, and 8.

      INDUCTION II: Patients with LR receive cytarabine IT, ADE chemotherapy, and bortezomib as in
      Induction I. Patients with HR receive cytarabine IT and MA chemotherapy as in Induction II,
      Arm A (HR patients) and bortezomib IV on days 1, 4, and 8.

      INTENSIFICATION I: Patients receive cytarabine IT and AE chemotherapy in Arm A,
      Intensification II, and bortezomib IV on days 1, 4, and 8. Patients who achieve CR proceed to
      Intensification II or stem cell transplantation (SCT) beginning on day 34. Patients with
      refractory disease are off protocol therapy.

      INTENSIFICATION II: Patients with LR receive cytarabine IT on day 1, MA chemotherapy as in
      Arm A, Induction II (HR patients), and bortezomib IV on days 1, 4, and 8. Patients with HR
      and no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, and 9 and
      asparaginase intramuscularly (IM) on days 2 and 9.

      STEM CELL TRANSPLANTATION (SCT) (HR patients with matched family [MFD] or unrelated donor):

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes once daily on
      days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of
      busulfan.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO beginning on day -2 and
      continuing until day 98 (matched sibling donor) or day 180 (with taper) (other
      related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched
      sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients
      with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.

      ARM C (COHORT 1):

      INDUCTION II: Patients receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on
      days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV
      over 1-2 hours on days 1-5, and sorafenib tosylate PO on days 9-36.

      INTENSIFICATION I: Patients receive cytarabine IT and AE chemotherapy in Arm A,
      Intensification II, and sorafenib tosylate PO on daily on days 6-28.

      INTENSIFICATION II: Patients receive cytarabine IT on day 1, MA chemotherapy as in Arm A,
      Induction II (HR patients), and sorafenib tosylate PO on days 7-34.

      STEM CELL TRANSPLANTATION (SCT) (HR patients with matched family [MFD] or unrelated donor):

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes once daily on
      days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of
      busulfan.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO beginning on day -2 and
      continuing until day 98 (matched sibling donor) or day 180 (with taper) (other
      related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched
      sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients
      with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.

      MAINTENANCE: Patients receive sorafenib tosylate PO starting on day 40-100 after completion
      of intensification II or SCT for one year.

      ARM C (COHORT 2):

      INDUCTION I: Patients receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I and
      sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including in Induction I and
      concurrently with chemotherapy).

      INDUCTION II: Patients receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on
      days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV
      over 1-2 hours on days 1-5, and sorafenib tosylate PO on days 9-36.

      INTENSIFICATION I: Patients receive cytarabine IT and AE chemotherapy in Arm A,
      Intensification II, and sorafenib tosylate PO on daily on days 6-28.

      INTENSIFICATION II: Patients receive cytarabine IT on day 1, MA chemotherapy as in Arm A,
      Induction II (HR patients), and sorafenib tosylate PO on days 7-34.

      STEM CELL TRANSPLANTATION (SCT) (HR patients with matched family [MFD] or unrelated donor):

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes once daily on
      days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of
      busulfan.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO beginning on day -2 and
      continuing until day 98 (matched sibling donor) or day 180 (with taper) (other
      related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched
      sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients
      with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.

      MAINTENANCE: Patients receive sorafenib tosylate PO starting on day 40-100 after completion
      of intensification II or SCT for one year.

      ARM C (COHORT 3):

      INDUCTION I: Patients receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I and
      sorafenib tosylate PO on days 11-28.

      INDUCTION II: Patients receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on
      days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV
      over 1-2 hours on days 1-5, and sorafenib tosylate PO on days 9-36.

      INTENSIFICATION I: Patients receive cytarabine IT and AE chemotherapy in Arm A,
      Intensification II, and sorafenib tosylate PO on daily on days 6-28.

      INTENSIFICATION II: Patients receive cytarabine IT on day 1, MA chemotherapy as in Arm A,
      Induction II (HR patients), and sorafenib tosylate PO on days 7-34.

      STEM CELL TRANSPLANTATION (SCT) (HR patients with matched family [MFD] or unrelated donor):

      CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes once daily on
      days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.

      TRANSPLANTATION: Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of
      busulfan.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO beginning on day -2 and
      continuing until day 98 (matched sibling donor) or day 180 (with taper) (other
      related/unrelated donors or cord blood) and methotrexate IV on days 1, 3, and 6 (matched
      sibling/cord blood donors) or days 1, 3, 6, and 11 (other related/unrelated donors). Patients
      with unrelated donors also receive antithymocyte globulin IV over 6-8 hours on days -3 to -1.

      MAINTENANCE: Patients receive sorafenib tosylate PO starting on day 40-100 after completion
      of intensification II or SCT for one year.

      ARM D:

      INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive
      cytarabine IT and ADE chemotherapy as in Arm A, Induction I. If patients are determined to be
      HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm
      C.

      After completion of study therapy, patients are followed up monthly for 6 months, every 2
      months for 6 months, every 4 months for 1 year, every 6 months for 1 year, and then yearly
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 20, 2011</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Actual">March 31, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS for Patients on Arm C, Cohort 1</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS for Patients on Arm C, Cohort 2</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS for Patients on Arm C, Cohort 3</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Patients on Arm C, Cohort 1</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Patients on Arm C, Cohort 2</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Patients on Arm C, Cohort 3</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Cumulative incidence estimates 3 year relapse rate defined as time from study entry to induction failure or relapse where deaths or secondary malignancies are competing events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The proportion of patients experiencing at least one grade 3 or higher non-hematologic toxicity and infection while on protocol therapy will be estimated along with the corresponding 95% confidence interval determined using a binomial exact method. Toxicity will be assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>The proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II will be estimated as well as the corresponding 95% confidence interval determined using a binomial exact method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Results represent the total scale scores from the parent report of the PedsQL™ 4.0 Generic Core Scales for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Scale Score From Parent-reported Cancer Module</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Results represent the total scale scores from the parent report of the PedsQL™ 3.0 Cancer Module for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Results represent the total scale scores from the parent report of the PedsQL™ Multidimensional Fatigue Scale for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bortezomib Clearance</measure>
    <time_frame>Day 8 of Induction II</time_frame>
    <description>Median and range of bortezomib clearance during Induction II.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sorafenib Steady State Concentration</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Median and range of sorafenib steady state concentration for Induction I.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Shortening Fraction</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Mean percentage change in shortening fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ejection Fraction</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The mean percentage change in ejection fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of GVHD Biomarker</measure>
    <time_frame>Up to day 28 after SCT</time_frame>
    <description>The mean serum concentration of the day 28 GVHD biomarker will be estimated as well as the corresponding 95% confidence interval.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Course Duration</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Descriptive statistics will be used to summarize length of hospitalization time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-related Mortality</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cumulative incidence estimates that account for competing events will be used to estimate treatment-related mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Hospitalization</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Descriptive statistics will be used to summarize length of hospitalization time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Remission Rate After 1 Course of Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>The proportion of patients achieving remission after 1 course of therapy will be estimated along with a corresponding 95% confidence interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Remission Rate After 2 Courses of Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>The proportion of patients achieving remission after 2 courses of therapy will be estimated along with a corresponding 95% confidence interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to Blood Count Recovery</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Cumulative incidence estimates that account for competing events will be used to estimate time to count recovery.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1645</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Leukemia Cutis</condition>
  <condition>Myeloid Neoplasm</condition>
  <condition>Myeloid Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description. Different dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description. May reassigned to Arm C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asparaginase</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <other_name>ASP-1</other_name>
    <other_name>Asparaginase II</other_name>
    <other_name>Asparaginase-E.Coli</other_name>
    <other_name>Colaspase</other_name>
    <other_name>Elspar</other_name>
    <other_name>Kidrolase</other_name>
    <other_name>L-Asnase</other_name>
    <other_name>L-ASP</other_name>
    <other_name>L-Asparaginase</other_name>
    <other_name>L-Asparagine Amidohydrolase</other_name>
    <other_name>Laspar</other_name>
    <other_name>Lcf-ASP</other_name>
    <other_name>Leucogen</other_name>
    <other_name>Leunase</other_name>
    <other_name>MK-965</other_name>
    <other_name>Paronal</other_name>
    <other_name>Re-82-TAD-15</other_name>
    <other_name>Serasa</other_name>
    <other_name>Spectrila</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IT or IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <other_name>CL 232315</other_name>
    <other_name>DHAD</other_name>
    <other_name>DHAQ</other_name>
    <other_name>Dihydroxyanthracenedione Dihydrochloride</other_name>
    <other_name>Mitoxantrone Dihydrochloride</other_name>
    <other_name>Mitoxantroni Hydrochloridum</other_name>
    <other_name>Mitozantrone Hydrochloride</other_name>
    <other_name>Mitroxone</other_name>
    <other_name>Neotalem</other_name>
    <other_name>Novantrone</other_name>
    <other_name>Onkotrone</other_name>
    <other_name>Pralifan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (Cohort 1)</arm_group_label>
    <arm_group_label>Arm C (Cohort 2)</arm_group_label>
    <arm_group_label>Arm C (Cohort 3)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be newly diagnosed with de novo acute myelogenous leukemia

          -  Patients with previously untreated primary AML who meet the customary criteria for AML
             with &gt;= 20% bone marrow blasts as set out in the 2008 World Health Organization (WHO)
             Myeloid Neoplasm Classification are eligible

               -  Attempts to obtain bone marrow either by aspirate or biopsy must be made unless
                  clinically prohibitive; in cases where it is clinically prohibitive, peripheral
                  blood with an excess of 20% blasts and in which adequate flow cytometric and
                  cytogenetics/fluorescent in situ hybridization (FISH) testing is feasible can be
                  substituted for the marrow exam at diagnosis

          -  Patients with &lt; 20% bone marrow blasts are eligible if they have:

               -  A karyotypic abnormality characteristic of de novo AML (t(8;21)(q22;q22),
                  inv(16)(p13q22) or t(16;16)(p13;q22) or 11q23 abnormalities

               -  The unequivocal presence of megakaryoblasts, or

               -  Biopsy proven isolated myeloid sarcoma (myeloblastoma; chloroma, including
                  leukemia cutis)

          -  Patients with any performance status are eligible for enrollment

          -  Prior therapy with hydroxyurea, all-trans retinoic acid (ATRA), corticosteroids (any
             route), and IT cytarabine given at diagnosis is allowed; hydroxyurea and ATRA must be
             discontinued prior to initiation of protocol therapy; patients who have previously
             received any other chemotherapy, radiation therapy or any other antileukemic therapy
             are not eligible for this protocol

        Exclusion Criteria:

          -  Patients with any of the following constitutional conditions are not eligible:

               -  Fanconi anemia

               -  Shwachman syndrome

               -  Any other known bone marrow failure syndrome

               -  Patients with constitutional trisomy 21 or with constitutional mosaicism of
                  trisomy 21 Note: enrollment may occur pending results of clinically indicated
                  studies to exclude these conditions

          -  Patients with any of the following oncologic diagnoses are not eligible:

               -  Any concurrent malignancy

               -  Juvenile myelomonocytic leukemia (JMML)

               -  Philadelphia chromosome positive AML

               -  Biphenotypic or bilineal acute leukemia

               -  Acute promyelocytic leukemia

               -  Acute myeloid leukemia arising from myelodysplasia

               -  Therapy-related myeloid neoplasms Note: enrollment may occur pending results of
                  clinically indicated studies to exclude these conditions

          -  Pregnancy and breast feeding

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible unless they have agreed not to breastfeed their
             infants

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Aplenc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USA Health Strada Patient Care Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardon Children's Medical Center</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202-3591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Downey Medical Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's and Women's Hospital Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Children's Hospital</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Cottage Hospital</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred I duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Memorial Health System</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golisano Children's Hospital of Southwest Florida</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Health Science Center - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital/Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital/Children's Hospital-Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Hospital</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Mountain States Tumor Institute</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital-Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Oak Lawn</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Children's Hospital-Park Ridge</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Hospital</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital and Health Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blank Children's Hospital</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Children's Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center Jefferson</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Children's Cancer Program</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889-5600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Floating Hospital for Children at Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ascension Saint John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University Clinical Center</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824-7016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen DeVos Children's Hospital at Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Children's Hospital-Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Regional</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Research Foundation CCOP</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunrise Hospital and Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Childhood Diseases/Cure 4 the Kids Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summerlin Hospital Medical Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Barnabas Medical Center</name>
      <address>
        <city>Livingston</city>
        <state>New Jersey</state>
        <zip>07039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Regional Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Steven and Alexandra Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center/Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novant Health Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Broadway Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center of Akron</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Childrens Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Children's Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Children's Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Emanuel Hospital and Health Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital - Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Children's Hospital</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health Richland Hospital</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BI-LO Charities Children's Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford USD Medical Center - Sioux Falls</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T C Thompson Children's Hospital</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tennessee Childrens Hospital</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center of Central Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Children's Hospital</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covenant Children's Hospital</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott and White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont and State Agricultural College</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of The King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Children's</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bridge Children's Hospital and Health Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Charleston Division</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Healthcare</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital Cancer Center Green Bay</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Center-Marshfield</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Children's Hospital</name>
      <address>
        <city>Hunter Regional Mail Centre</city>
        <state>New South Wales</state>
        <zip>2310</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital-Brisbane</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital for Children</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janeway Child Health Centre</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster Children's Hospital at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Health Sciences Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Montreal Children's Hospital of the MUHC</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Starship Children's Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1145</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children's Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00912</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <results_first_submitted>April 20, 2020</results_first_submitted>
  <results_first_submitted_qc>June 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Sarcoma, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT01371981/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Results in the Participant Flow table summarize final (or analysis) arm assignment. Therefore, results for patients on Arms A, B, and D do not include any patient who transferred to Arm C.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A</title>
          <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days 1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days 2,9.
SCT:
pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="P2">
          <title>Arm B</title>
          <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="P3">
          <title>Arm C (Cohort 1)</title>
          <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
        </group>
        <group group_id="P4">
          <title>Arm C (Cohort 2)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INT I: Pts receive cytarabine IT and AE as in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="P5">
          <title>Arm C (Cohort 3)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="P6">
          <title>Arm D</title>
          <description>INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="591"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="382"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="399"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="368"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not start treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="B3">
          <title>Arm C (Cohort 1)</title>
          <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
        </group>
        <group group_id="B4">
          <title>Arm C (Cohort 2)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="B5">
          <title>Arm C (Cohort 3)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="B6">
          <title>Arm D</title>
          <description>INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="580"/>
            <count group_id="B2" value="591"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="47"/>
            <count group_id="B6" value="382"/>
            <count group_id="B7" value="1645"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5940" spread="6.6172"/>
                    <measurement group_id="B2" value="9.4322" spread="6.6408"/>
                    <measurement group_id="B3" value="11.7930" spread="4.9715"/>
                    <measurement group_id="B4" value="12.4961" spread="5.0103"/>
                    <measurement group_id="B5" value="11.7907" spread="5.0134"/>
                    <measurement group_id="B6" value="9.1600" spread="6.6186"/>
                    <measurement group_id="B7" value="9.5721" spread="6.5691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="203"/>
                    <measurement group_id="B7" value="858"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="286"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="179"/>
                    <measurement group_id="B7" value="787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="457"/>
                    <measurement group_id="B2" value="465"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="273"/>
                    <measurement group_id="B7" value="1269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                    <measurement group_id="B2" value="413"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="257"/>
                    <measurement group_id="B7" value="1148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="514"/>
                    <measurement group_id="B2" value="515"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="334"/>
                    <measurement group_id="B7" value="1444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Arms A and B are limited to patients without high allelic ratio FLT3/ITD+ mutations.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Arms A and B are limited to patients without high allelic ratio FLT3/ITD+ mutations.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.64" lower_limit="41.34" upper_limit="49.83"/>
                    <measurement group_id="O2" value="46.95" lower_limit="42.69" upper_limit="51.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EFS for Patients on Arm C, Cohort 1</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
        </group_list>
        <measure>
          <title>EFS for Patients on Arm C, Cohort 1</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="6.01" upper_limit="50.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EFS for Patients on Arm C, Cohort 2</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>EFS for Patients on Arm C, Cohort 2</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.12" lower_limit="37.33" upper_limit="71.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EFS for Patients on Arm C, Cohort 3</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>EFS for Patients on Arm C, Cohort 3</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year EFS, defined as the time from study entry until induction failure, relapse, secondary malignancy, or death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of EFS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.18" lower_limit="42.30" upper_limit="71.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Arms A and B are limited to patients without high allelic ratio FLT3/ITD+ mutations.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Arms A and B are limited to patients without high allelic ratio FLT3/ITD+ mutations.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.04" lower_limit="60.75" upper_limit="68.98"/>
                    <measurement group_id="O2" value="68.45" lower_limit="64.33" upper_limit="72.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS for Patients on Arm C, Cohort 1</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
        </group_list>
        <measure>
          <title>OS for Patients on Arm C, Cohort 1</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.67" lower_limit="15.25" upper_limit="66.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS for Patients on Arm C, Cohort 2</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>OS for Patients on Arm C, Cohort 2</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.77" lower_limit="45.37" upper_limit="78.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS for Patients on Arm C, Cohort 3</title>
        <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>OS for Patients on Arm C, Cohort 3</title>
          <description>The Kaplan-Meier method will be used to estimate 3-year OS, defined as the time from study entry until death.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from analyses of OS. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.84" lower_limit="44.09" upper_limit="75.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
        <description>Cumulative incidence estimates 3 year relapse rate defined as time from study entry to induction failure or relapse where deaths or secondary malignancies are competing events.</description>
        <time_frame>Up to 3 years</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arms C or D are excluded. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Results are limited to patients on Arms A and B without high allelic ratio FLT3/ITD+ mutations.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations</title>
          <description>Cumulative incidence estimates 3 year relapse rate defined as time from study entry to induction failure or relapse where deaths or secondary malignancies are competing events.</description>
          <population>Patients ineligible, did not start treatment, or on Arms C or D are excluded. Arm D patients who were not eligible for Arm C by the end of induction I were declared off study per protocol; thus, no outcome data were collected for Arm D patients. Results are limited to patients on Arms A and B without high allelic ratio FLT3/ITD+ mutations.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="552"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67" lower_limit="42.36" upper_limit="50.86"/>
                    <measurement group_id="O2" value="46.65" lower_limit="42.39" upper_limit="50.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy</title>
        <description>The proportion of patients experiencing at least one grade 3 or higher non-hematologic toxicity and infection while on protocol therapy will be estimated along with the corresponding 95% confidence interval determined using a binomial exact method. Toxicity will be assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Patients ineligible or who did not start treatment are excluded from results.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
          <group group_id="O5">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
          <group group_id="O6">
            <title>Arm D</title>
            <description>INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy</title>
          <description>The proportion of patients experiencing at least one grade 3 or higher non-hematologic toxicity and infection while on protocol therapy will be estimated along with the corresponding 95% confidence interval determined using a binomial exact method. Toxicity will be assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).</description>
          <population>Patients ineligible or who did not start treatment are excluded from results.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="559"/>
                <count group_id="O2" value="575"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8819" lower_limit="0.8522" upper_limit="0.9075"/>
                    <measurement group_id="O2" value="0.9217" lower_limit="0.8967" upper_limit="0.9423"/>
                    <measurement group_id="O3" value="0.9167" lower_limit="0.6152" upper_limit="0.9979"/>
                    <measurement group_id="O4" value="0.9394" lower_limit="0.7977" upper_limit="0.9926"/>
                    <measurement group_id="O5" value="0.9149" lower_limit="0.7962" upper_limit="0.9763"/>
                    <measurement group_id="O6" value="0.0239" lower_limit="0.0110" upper_limit="0.0450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II</title>
        <description>The proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II will be estimated as well as the corresponding 95% confidence interval determined using a binomial exact method.</description>
        <time_frame>Up to 8 weeks</time_frame>
        <population>Patients ineligible, did not start treatment, on Arms C, D are excluded from results. Complete MRD results were not collected for Arm D patients due to being declared off study at end of induction I. Results limited to High Risk patients without high allelic ratio FLT3/ITD+ mutations and with evaluable MRD data from end of Induction I and II.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II</title>
          <description>The proportion of high risk children without HR FLT3/ITD+ converting from positive MRD at end of Induction I to negative MRD at the end of Induction II will be estimated as well as the corresponding 95% confidence interval determined using a binomial exact method.</description>
          <population>Patients ineligible, did not start treatment, on Arms C, D are excluded from results. Complete MRD results were not collected for Arm D patients due to being declared off study at end of induction I. Results limited to High Risk patients without high allelic ratio FLT3/ITD+ mutations and with evaluable MRD data from end of Induction I and II.</population>
          <units>Proportion of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5000" lower_limit="0.3830" upper_limit="0.6170"/>
                    <measurement group_id="O2" value="0.5238" lower_limit="0.4119" upper_limit="0.6340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module</title>
        <description>Results represent the total scale scores from the parent report of the PedsQL™ 4.0 Generic Core Scales for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
        <time_frame>Up to 14 days</time_frame>
        <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module</title>
          <description>Results represent the total scale scores from the parent report of the PedsQL™ 4.0 Generic Core Scales for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
          <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" lower_limit="55.7" upper_limit="81.5"/>
                    <measurement group_id="O2" value="67.8" lower_limit="52.2" upper_limit="83.7"/>
                    <measurement group_id="O3" value="71.3" lower_limit="58.7" upper_limit="87.5"/>
                    <measurement group_id="O4" value="61.6" lower_limit="46.2" upper_limit="81.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Scale Score From Parent-reported Cancer Module</title>
        <description>Results represent the total scale scores from the parent report of the PedsQL™ 3.0 Cancer Module for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
        <time_frame>Up to 14 days</time_frame>
        <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Scale Score From Parent-reported Cancer Module</title>
          <description>Results represent the total scale scores from the parent report of the PedsQL™ 3.0 Cancer Module for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
          <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.2" lower_limit="53.7" upper_limit="78.7"/>
                    <measurement group_id="O2" value="65.8" lower_limit="53.7" upper_limit="77.9"/>
                    <measurement group_id="O3" value="74.9" lower_limit="69.0" upper_limit="81.7"/>
                    <measurement group_id="O4" value="63.7" lower_limit="56.9" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module</title>
        <description>Results represent the total scale scores from the parent report of the PedsQL™ Multidimensional Fatigue Scale for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
        <time_frame>Up to 14 days</time_frame>
        <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module</title>
          <description>Results represent the total scale scores from the parent report of the PedsQL™ Multidimensional Fatigue Scale for timepoint 1 (up to 14 days from start of therapy). Items are reverse-scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Therefore, a higher number is a better outcome. The total score is the sum of all the items divided by the number of items answered on all the scales. &quot;Scores on a scale&quot; is used for a unit of measure.</description>
          <population>Patients ineligible or who did not start treatment are excluded from results. Patients on Arms C (cohort 3) or Arm D are excluded due to enrolling post quality of life study accrual completion. Results are limited to only patients with an evaluable total scale score.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="45.8" upper_limit="75.0"/>
                    <measurement group_id="O2" value="58.1" lower_limit="44.4" upper_limit="73.6"/>
                    <measurement group_id="O3" value="71.2" lower_limit="52.8" upper_limit="87.5"/>
                    <measurement group_id="O4" value="48.2" lower_limit="30.6" upper_limit="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bortezomib Clearance</title>
        <description>Median and range of bortezomib clearance during Induction II.</description>
        <time_frame>Day 8 of Induction II</time_frame>
        <population>Only eligible patients on Arm B with evaluable Bortezomib PK clearance data during Induction II are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
        </group_list>
        <measure>
          <title>Bortezomib Clearance</title>
          <description>Median and range of bortezomib clearance during Induction II.</description>
          <population>Only eligible patients on Arm B with evaluable Bortezomib PK clearance data during Induction II are reported.</population>
          <units>Liters/hour/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" lower_limit="3.52" upper_limit="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sorafenib Steady State Concentration</title>
        <description>Median and range of sorafenib steady state concentration for Induction I.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Data reported from Arm C were collected and analyzed regardless of the cohort as pre-specified in the study protocol. Only eligible patients on Arm C with evaluable Sorafenib steady state concentration data during Induction I are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C</title>
            <description>Arm C (Cohort 1) IND II:cytarabine IT; cytarabine IV; daunorubicin hydrochloride IV; etoposide IV; sorafenib tosylate PO INT I:cytarabine IT; AE chemotherapy as Arm A, Intensification II; sorafenib tosylate PO INT II:cytarabine IT; MA chemotherapy as Arm A, Induction II (HR patients); sorafenib tosylate PO.
SCT (HR pts w/ matched family [MFD] or unrelated donor): fludarabine phosphate IV; busulfan IV; allogeneic SCT; GVHD prophylaxis.
MAINTENANCE:sorafenib tosylate PO
Arm C (Cohort 2 and 3) IND I:cytarabine IT; ADE as Arm A, IND I; sorafenib tosylate PO IND II:cytarabine IT; cytarabine IV; daunorubicin hydrochloride IV; etoposide IV; sorafenib tosylate PO INT I:cytarabine IT; AE as Arm A, INT II, &amp; sorafenib tosylate PO INT II:cytarabine IT; MA as Arm A, IND II (HR patients); sorafenib tosylate PO. SCT (HR pts w/ matched family [MFD] or unrelated donor): fludarabine phosphate IV; busulfan IV; allogeneic SCT; GVHD prophylaxis.
MAINTENANCE:sorafenib tosylate PO</description>
          </group>
        </group_list>
        <measure>
          <title>Sorafenib Steady State Concentration</title>
          <description>Median and range of sorafenib steady state concentration for Induction I.</description>
          <population>Data reported from Arm C were collected and analyzed regardless of the cohort as pre-specified in the study protocol. Only eligible patients on Arm C with evaluable Sorafenib steady state concentration data during Induction I are reported.</population>
          <units>Nanogram/Milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1090.0" lower_limit="290.0" upper_limit="4740.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Shortening Fraction</title>
        <description>Mean percentage change in shortening fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from results. Shortening fraction data were not collected at end of Induction I for patients enrolled to Arm D. Results are limited to patients with evaluable shortening fraction data from study entry and at end of Induction I .</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
          <group group_id="O5">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Shortening Fraction</title>
          <description>Mean percentage change in shortening fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from results. Shortening fraction data were not collected at end of Induction I for patients enrolled to Arm D. Results are limited to patients with evaluable shortening fraction data from study entry and at end of Induction I .</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="503"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8445" spread="5.2070"/>
                    <measurement group_id="O2" value="-2.6298" spread="6.7797"/>
                    <measurement group_id="O3" value="-2.2333" spread="4.7689"/>
                    <measurement group_id="O4" value="-3.6700" spread="5.3115"/>
                    <measurement group_id="O5" value="-3.4246" spread="4.8583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ejection Fraction</title>
        <description>The mean percentage change in ejection fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
        <time_frame>Up to 4 weeks</time_frame>
        <population>Patients ineligible, did not start treatment, or on Arm D are excluded from results. Ejection fraction data were not collected at end of Induction I for patients enrolled to Arm D. Results are limited to patients with evaluable ejection fraction data from study entry and at end of Induction I .</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
          <group group_id="O5">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ejection Fraction</title>
          <description>The mean percentage change in ejection fraction from baseline to the end of Induction I will be determined for eligible patients enrolled on Arms A, B and C.</description>
          <population>Patients ineligible, did not start treatment, or on Arm D are excluded from results. Ejection fraction data were not collected at end of Induction I for patients enrolled to Arm D. Results are limited to patients with evaluable ejection fraction data from study entry and at end of Induction I .</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="425"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0272" spread="7.1843"/>
                    <measurement group_id="O2" value="-2.3453" spread="7.6974"/>
                    <measurement group_id="O3" value="-7.5000" spread="12.5340"/>
                    <measurement group_id="O4" value="-5.1997" spread="7.0532"/>
                    <measurement group_id="O5" value="-3.4624" spread="6.7516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentrations of GVHD Biomarker</title>
        <description>The mean serum concentration of the day 28 GVHD biomarker will be estimated as well as the corresponding 95% confidence interval.</description>
        <time_frame>Up to day 28 after SCT</time_frame>
        <population>Data were never collected</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Cohort 1)</title>
            <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
          </group>
          <group group_id="O4">
            <title>Arm C (Cohort 2)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
          </group>
          <group group_id="O5">
            <title>Arm C (Cohort 3)</title>
            <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE as in Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentrations of GVHD Biomarker</title>
          <description>The mean serum concentration of the day 28 GVHD biomarker will be estimated as well as the corresponding 95% confidence interval.</description>
          <population>Data were never collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Course Duration</title>
        <description>Descriptive statistics will be used to summarize length of hospitalization time.</description>
        <time_frame>Up to 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Treatment-related Mortality</title>
        <description>Cumulative incidence estimates that account for competing events will be used to estimate treatment-related mortality.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Length of Hospitalization</title>
        <description>Descriptive statistics will be used to summarize length of hospitalization time.</description>
        <time_frame>Up to 6 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Remission Rate After 1 Course of Therapy</title>
        <description>The proportion of patients achieving remission after 1 course of therapy will be estimated along with a corresponding 95% confidence interval.</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Remission Rate After 2 Courses of Therapy</title>
        <description>The proportion of patients achieving remission after 2 courses of therapy will be estimated along with a corresponding 95% confidence interval.</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Blood Count Recovery</title>
        <description>Cumulative incidence estimates that account for competing events will be used to estimate time to count recovery.</description>
        <time_frame>Up to 6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While patients were on protocol therapy (including up to 4 courses, stem cell transplant course, and 3 courses of maintenance therapy)) or up to 7 years in follow-up.</time_frame>
      <desc>Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution via expedited reporting (NCI AdEERs / CAeRs). All remaining CTCAEs collected by means other than expedited reporting are non-serious and are reported in the &quot;AE Other&quot; table. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1, 3, 5; etoposide IV 1-2 hours days1-5.
IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1, MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4, mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1, AE chemo with high-dose cytarabine IV over 1-3 hours, etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1, 2, 8, 9; asparaginase intramuscularly (IM) days2,9.
SCT:
: pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2, busulfan IV over 2 hours 4 times daily days -5 to -2.
Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I, Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8.
IND II: LR pts receive cytarabine IT, ADE chemotherapy, bortezomib as in IND I. HR pts receive cytarabine IT, MA as in IND II, Arm A (HR patients) and bortezomib IV on days 1, 4, 8.
INT I: Pts receive cytarabine IT and AE in Arm A, Intensification II, and bortezomib IV on days 1, 4, 8. INT II: LR pts receive cytarabine IT on day 1, MA as in Arm A, IND II (HR patients), and bortezomib IV on days 1, 4, 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1, 2, 8, 9 and asparaginase intramuscularly (IM) on days 2 and 9.
SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.</description>
        </group>
        <group group_id="E3">
          <title>Arm C (Cohort 1)</title>
          <description>IND II: Pts receive cytarabine IT on day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes on days 1, 3, and 5, etoposide IV over 1-2 hours on days 1-5, sorafenib tosylate PO on days 9-36.
INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A, Intensification II, and sorafenib tosylate PO on daily on days 6-28.
INT II: Pts receive cytarabine IT on day 1, MA chemotherapy as in Arm A, Induction II (HR patients), sorafenib tosylate PO on days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2, busulfan IV over 2 hours 4 times daily on days -5 to -2.
Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.
MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.</description>
        </group>
        <group group_id="E4">
          <title>Arm C (Cohort 2)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I &amp; concurrently with chemo).
IND II: Pts receive cytarabine IT day (d) 1, cytarabine IV over 1-30 minutes on d 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours d 1-5, sorafenib tosylate PO d 9-36.
INTE I: Pts receive cytarabine IT and AE in Arm A, INT II, and sorafenib tosylate PO on daily d 6-28.
INT II: Pts receive cytarabine IT on d 1, MA as in Arm A, IND II (HR pts), sorafenib tosylate PO d 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2, busulfan IV over 2 hours 4 times daily d -5 to -2.
Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="E5">
          <title>Arm C (Cohort 3)</title>
          <description>IND I: Pts receive cytarabine IT &amp; ADE as in Arm A, IND I &amp; sorafenib tosylate PO days 11-28.
IND II: Pts receive cytarabine IT day 1, cytarabine IV over 1-30 minutes on days 1-8, daunorubicin hydrochloride IV over 1-15 minutes days 1, 3, 5, etoposide IV over 1-2 hours days 1-5, sorafenib tosylate PO days 9-36.
INT I: Pts receive cytarabine IT &amp; AE cin Arm A, INT II, &amp; sorafenib tosylate PO daily days 6-28.
INT II: Pts receive cytarabine IT day 1, MA as in Arm A, IND II (HR patients), &amp; sorafenib tosylate PO days 7-34.
SCT (HR patients with matched family [MFD] or unrelated donor):
Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2.
Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.</description>
        </group>
        <group group_id="E6">
          <title>Arm D</title>
          <description>INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A, Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="305" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hemolytic uremic syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystole</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Optic nerve disorder</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Papilledema</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cecal infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Duodenal infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophageal infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Periorbital infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Postoperative hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Central nervous system necrosis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Laryngeal mucositis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Mediastinal hemorrhage</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tracheal mucositis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythroderma</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Toxic epidermal necrolysis</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>Adeers submitted</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="506" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="529" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bone marrow hypocellular</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Asystole</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pulmonary valve disease</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Restrictive cardiomyopathy</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, familial and genetic disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Periorbital edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vitreous hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anal mucositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophageal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophageal ulcer</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ileal perforation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rectal mucositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Retroperitoneal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Small intestinal mucositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema face</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bone infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cecal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Esophageal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gallbladder infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="275" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Infective myositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Joint infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lymph gland infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Penile infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Periorbital infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pleural infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Salivary gland infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Splenic infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vulval infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Venous injury</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Fibrinogen decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Iron overload</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Tumor lysis syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Avascular necrosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Psychiatric disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchopleural fistula</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Laryngeal edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Laryngeal mucositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Laryngeal stenosis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pharyngeal hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pharyngeal mucositis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pleural hemorrhage</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sleep apnea</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bullous dermatitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Erythroderma</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Capillary leak syndrome</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <description>Adeers not subm</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="559"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="575"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="376"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

